Analytical Methods with Clinical Trial and Future Aspects of Vonoprazan : A Systemic Review

Vyas,, Amitkumar J; Santoki, Nensi D; Patel, Ajay I; Dudhrejiya, Ashvin V; Shah, Sunny R; Sheth, Devang B; Dholakia, Sandip P

doi:10.48309/jmnc.2023.4.4

Document Type : Review Article

Authors

¹ B. K. Mody Government Pharmacy College, Rajkot, Gujarat, India

² L. M. College of Pharmacy, Ahmedabad, Gujarat, India

https://doi.org/10.48309/jmnc.2023.4.4

Abstract

Nowadays, use of antacids has drastically increased due to an increase in the intake of drugs with certain side effects, in which the dominant ‘acid release cycle’ is disturbed. This resulted in the inclusion of Proton pump inhibitors in a major number of prescriptions. In individuals with gastroesophageal reflux disease and concurrent Helicobacter Pylori infection, proton pump inhibitors exhibit a significant limitation in providing relief from symptoms or adressing lingering issues associated with the sympathetic system, particularly during periods of rest such as sleep. Furthermore, this article summarises vonoprazan's effects on ‘triple drug therapy’. Through its inhibition of the stomach’s H+/K+ ATPase, Vonoprazan, a novel potassium-competitive acid blocker, has the potential to provide a reversible mechanism of action, leading to acid supression.It is anticipated that vonoprazan-based addiction therapy would be more effective for treatment for shorter period of time. In this study, the latest information provides a concise overview of the chemistry, biological properties, pharmacological, analytical methods, and clinical trials of Vonoprazan.

Graphical Abstract

Keywords

Main Subjects

Pharmaceutical sciences & Medicinal

References

1]. Soll A.H., Achord J.L., Bozymski G., Brooks S., Lanza F., Lyon D., Meyer G., Reinus J., Schuster M., Achord J. Jama, 1996, 275:622 [Crossref], [Google Scholar], [Publisher]

[2]. Axon A. Helicobacter, 2014, 19:68 [Crossref], [Google Scholar], [Publisher]

[3]. Fock K.M., Ang T.L., Bee L.C., Lee E.J.D. Clinical Pharmacokinetics, 2008, 47:1 [Crossref], [Google Scholar], [Publisher]

[4]. Cheng H.C., Sheu B.S. World Journal of Gastrointestinal Endoscopy, 2011, 3:49 [Crossref], [Google Scholar], [Publisher]

[5]. Furuta T., Sugimoto M., Shirai N. Molecular diagnosis & therapy, 2012, 16:223 [Crossref], [Google Scholar], [Publisher]

[6]. Soll A.H., Achord J.L., Bozymski G., Brooks S., Lanza F., Lyon D., Meyer G., Reinus J., Schuster M., Achord J. Jama, 1996, 275:622 [Crossref], [Google Scholar], [Publisher]

[7]. Hooi J.K., Lai W.Y., Ng W.K., Suen M.M., Underwood F.E., Tanyingoh D., Malfertheiner P., Graham D.Y., Wong V.W., Wu J.C. Gastroenterology, 2017, 153:420 [Crossref], [Google Scholar], [Publisher]

[8]. Syam A.F., Miftahussurur M., Makmun D., Nusi I.A., Zain L.H., Zulkhairi, Akil F., Uswan W.B., Simanjuntak D., Uchida T. PloS one, 2015, 10:e0140186 [Crossref], [Google Scholar], [Publisher]

[9]. Suzuki H., Mori H. Journal of gastroenterology, 2018, 53:354 [Crossref], [Google Scholar], [Publisher]

[10]. Miftahussurur M., Pratama Putra B., Yamaoka Y. Pharmaceuticals, 2020, 13:276 [Crossref], [Google Scholar], [Publisher]

[11]. Sugimoto M., Yamaoka Y. Frontiers in Pharmacology, 2019, 9:1560 [Crossref], [Google Scholar], [Publisher]

[12]. Jenkins H., Sakurai Y., Nishimura A., Okamoto H., Hibberd M., Jenkins R., Yoneyama T., Ashida K., Ogama Y., Warrington S. Alimentary pharmacology & therapeutics, 2015, 41:636 [Crossref], [Google Scholar], [Publisher]

[13]. Shin J.M., Inatomi N., Munson K., Strugatsky D., Tokhtaeva E., Vagin O., Sachs G. Journal of Pharmacology and Experimental Therapeutics, 2011, 339:412 [Crossref], [Google Scholar], [Publisher]

[14]. Hori Y., Imanishi A., Matsukawa J., Tsukimi Y., Nishida H., Arikawa Y., Hirase K., Kajino M., Inatomi N. Journal of Pharmacology and Experimental Therapeutics, 2010, 335:231 [Crossref], [Google Scholar], [Publisher]

[15] Drug profile and information pf Vonoprazan [Publisher]

[16] Yu Q.Y., Zeng H., Yao K., Li J.Q., Liu Y. Synthetic communications, 2017, 47:1169 [Crossref], [Google Scholar], [Publisher]

[17]. Ishida M., Tsuchiya M., Naito J., Kawazoe H., Watanabe D., Nonaka Y., Sano M., Sakai H., Suzuki A., Kumada K. Kidney International, 2022, 102:666 [Crossref], [Google Scholar], [Publisher]

[18]. Oshima T., Miwa H. Journal of Neurogastroenterology and Motility, 2018, 24:334 [Crossref], [Google Scholar], [Publisher]

[19]. Sakurai Y., Shiino M., Okamoto H., Nishimura A., Nakamura K., Hasegawa S. Advances in therapy, 2016, 33:1519 [Crossref], [Google Scholar], [Publisher]

[20]. Kong W., Sun B., Wang Z., Zheng X., Zhao K., Chen Y., Zhang J., Liu P., Zhu L., Xu R.. Acta Pharmacologica Sinica, 2020, 41:852 [Crossref], [Google Scholar], [Publisher]

[21]. Wang M.S., Gong Y., Zhuo L.S., Shi X.-X., Tian Y.-G., Huang C.-K., Huang W., Yang G.-F. Research, 2022, [Crossref], [Google Scholar], [Publisher]

[22]. Echizen H. Clinical Pharmacokinetics, 2016, 55:409 [Crossref], [Google Scholar], [Publisher]

[23]. Yamasaki H., Kawaguchi N., Nonaka M., Takahashi J., Morohashi A., Hirabayashi H., Moriwaki T., Asahi S. Xenobiotica, 2017, 47:1027 [Crossref], [Google Scholar], [Publisher]

[24]. Jenkins H., Jenkins R., Patat A. Clinical drug investigation, 2017, 37:311 [Crossref], [Google Scholar], [Publisher]

[25]. van Haarst A., Smith S., Garvin C., Benrimoh N., Paglialunga S. Clinical Pharmacology & Therapeutics, 2023, 113:816 [Crossref], [Google Scholar], [Publisher]

[26]. Bolleddula J., Gopalakrishnan S., Hu P., Dong J., Venkatakrishnan K. Clinical and Translational Science, 2022, 15:2075 [Crossref], [Google Scholar], [Publisher]

[27]. Greenberg R.G., Melloni C., Wu H., Gonzalez D., Ku L., Hill K.D., Hornik C.P., Zheng N., Jiang W., Cohen-Wolkowiez M. Clinical neuropharmacology, 2016, 39:232 [Crossref], [Google Scholar], [Publisher]

[28]. Mulford D.J., Ramsden D., Zhang L., Michon I., Leifke E., Smith N., Jones H.M., Scarpignato C. CPT: Pharmacometrics & Systems Pharmacology, 2023, 12:532 [Crossref], [Google Scholar], [Publisher]

[29]. Inaba T., Iwamuro M., Toyokawa T., Okada H. Alimentary pharmacology & therapeutics, 2016, 43:179 [Crossref], [Google Scholar], [Publisher]

[30]. Kawashima K., Ishihara S., Kinoshita Y. Digestive and Liver Disease, 2016, 48:688 [Crossref], [Google Scholar], [Publisher]

[31]. Suzuki S., Kusano C., Horii T., Ichijima R., Ikehara H. Digestion, 2022, 103:62 [Crossref], [Google Scholar], [Publisher]

[32]. FDA Approved drug products: VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK co-packaged for oral use [Publisher]

[33]. Abdelazim A.H., Abdel-Fattah A., Osman A.O., Abdel-Kareem R.F., Ramzy S. Journal of AOAC International, 2023, 106:490 [Crossref], [Google Scholar], [Publisher]

[34]. Yoneyama T., Teshima K., Jinno F., Kondo T., Asahi S. Journal of Chromatography B, 2016, 1015:42 [Crossref], [Google Scholar], [Publisher]

[35]. Luo Z., Liu A., Liu Y., Wang G., Chen X., Wang H., Li M., Zhang H., Qiu Y., Zhai H. Journal of pharmaceutical and biomedical analysis, 2018, 149:133 [Crossref], [Google Scholar], [Publisher]

[36]. Jiang Q., Liu W., Li X., Zhang T., Wang Y., Liu X. Journal of separation science, 2016, 39:350 [Crossref], [Google Scholar], [Publisher]

[37]. Al-Qahtani S.D., Al-nami S.Y. Arabian Journal of Chemistry, 2021, 14:103254 [Crossref], [Google Scholar], [Publisher]

[38]. Recommendations of the SEC (Gastroenterology & Hepatology) 2022 [Publisher]

[39]. Songjun L., Huaming L.F.M., Xiaoyan Z.Q.L., Gangqiang L.L.L.W. Preparation method of Vonoprazan. chinese patent CN109232537B 2021. [Publisher]

[40]. Shaoyi K., Niangen C., Lin Z.L.Y.X.C. The preparation method of Vonoprazan fumarate. chinese patent CN105130955B 2015. [Publisher]

[41]. Shen C.Y., Yao X., Yuncheng. The preparation technology of Vonoprazan fumarate. chinese patent CN105294653B 2015. [Publisher]

[42]. Yansun N., Maocong B.Y., Qingshuang M., Xiaoguang W. The preparation method of Vonoprazan fumarate. chinese patent CN106366071B 2016. [Publisher]

[43]. Lixin W., Zhengquan Z., Tao P., Juan W. A kind of preparation method of Vonoprazan fumarate. chinese patent CN108503621A 2017. [Publisher]

[44]. Yu Rui Chen Yu Ye Kai for the Preparation method of vonoprazan fumarate. chinese patent CN110452222B 2019. [Publisher]

[45]. Clinical trials of vonoprazan [Publisher]

[46]. Salman S., Ahmed M.R. Chem. Methodol., 2022, 6:997 [Crossref], [Publisher]

[47]. Najdsepas H., Rahimzadeh N., haghighikian M., Maddahali M., Milani Fard M. Eurasian J. Sci. Technol., 2022, 2:176 [Crossref], [Publisher]

[48]. Mohammed A.Y., Ahamed L.S. Chem. Methodol., 2022, 6:813 [Crossref], [Publisher]

[49]. Salehi Sardoei A. Int. J. Adv. Biol. Biomed. Res, 2022, 10:44 [Crossref], [Google Scholar], [Publisher]

[50]. Gharayagh-Zandi D., Makouee S. IJASHSS, 2022, 11:11 [Crossref], [Google Scholar], [Publisher]

Journal of Medicinal and Nanomaterials Chemistry

Analytical Methods with Clinical Trial and Future Aspects of Vonoprazan : A Systemic Review

References

References

Volume 5, Issue 4
December 2023
Pages 283-296

Analytical Methods with Clinical Trial and Future Aspects of Vonoprazan : A Systemic Review

References

References

Volume 5, Issue 4December 2023Pages 283-296

Volume 5, Issue 4
December 2023
Pages 283-296